The mechanisms responsible for cellular iron homeostasis are increasingly implicated in degenerative disease and aging. This is exemplified by Friedreich ataxia (FRDA), a neurodegenerative and cardiac disease caused by a deficiency of frataxin, a mitochondrial iron-binding protein. We were the first to report that frataxin binds iron. We have shown that frataxin self-assembles and functions as both a Fe(ll)- chaperone to diverse iron-binding proteins, and as a Fe(lll)-storage molecule with ferroxidation and mineralization activities that enable iron detoxification. We propose to test the following model: (i) The main function of frataxin is to detoxify redox-active iron in the mitochondrial matrix;(ii) frataxin accomplishes this by binding labile Fe(ll) imported from the cytoplasm or released in the matrix from superoxide-induced oxidation of [4Fe-4S] clusters;(iii) frataxin detoxifies labile Fe(ll) by promoting its insertion into iron-sulfur clusters and heme or its oxidation and incorporation into a stable mineral that is inactive in radical-generating reactions;(vi) while frataxin monomer only serves as a Fe(ll)-donor, assembly gives frataxin both the surface plasticity to interact with different iron-binding proteins and the structure to oxidize and store surplus iron. Using a collection of mutant frataxin proteins, we will dissect the mechanisms that enable frataxin to self- assemble (Aim 1), control iron toxicity (Aim 2), and donate Fe(ll) to different proteins (Aim 3). Frataxin variants with specific defects in self-assembly, iron uptake, and protein-protein interactions will be studied in S. cerevisiae cells with different endogenous sources of oxidative stress (Aim 4). Screens for genetic suppressors and synthetic lethal interactions of frataxin mutations will be used to identify proteins that act on frataxin improving its function or proteins that work with frataxin to detoxify mitochondrial iron (Aim 5). Our goal is to characterize the anti-oxidant function of frataxin and discover new determinants of oxidative stress resistance.

Public Health Relevance

TO PUBLIC HEALTH The ability to handle iron efficiently and safely is critical to cell survival. By elucidating the underlying mechanisms, our work will help to identify fundamental sources of oxidative damage, degenerative disease, and unhealthy aging, and to develop preventive strategies and effective treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG015709-14
Application #
7813787
Study Section
Cellular Mechanisms in Aging and Development Study Section (CMAD)
Program Officer
Finkelstein, David B
Project Start
1997-09-30
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
14
Fiscal Year
2010
Total Cost
$228,657
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Galeano, B K; Ranatunga, W; Gakh, O et al. (2017) Zinc and the iron donor frataxin regulate oligomerization of the scaffold protein to form new Fe-S cluster assembly centers. Metallomics 9:773-801
Ranatunga, Wasantha; Gakh, Oleksandr; Galeano, Belinda K et al. (2016) Architecture of the Yeast Mitochondrial Iron-Sulfur Cluster Assembly Machinery: THE SUB-COMPLEX FORMED BY THE IRON DONOR, Yfh1 PROTEIN, AND THE SCAFFOLD, Isu1 PROTEIN. J Biol Chem 291:10378-98
Gakh, Oleksandr; Ranatunga, Wasantha; Smith 4th, Douglas Y et al. (2016) Architecture of the Human Mitochondrial Iron-Sulfur Cluster Assembly Machinery. J Biol Chem 291:21296-21321
Söderberg, Christopher; Gillam, Mallory E; Ahlgren, Eva-Christina et al. (2016) The Structure of the Complex between Yeast Frataxin and Ferrochelatase: CHARACTERIZATION AND PRE-STEADY STATE REACTION OF FERROUS IRON DELIVERY AND HEME SYNTHESIS. J Biol Chem 291:11887-98
Jobling, Rebekah K; Assoum, Mirna; Gakh, Oleksandr et al. (2015) PMPCA mutations cause abnormal mitochondrial protein processing in patients with non-progressive cerebellar ataxia. Brain 138:1505-17
Isaya, Grazia (2014) Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease. Front Pharmacol 5:29
Soderberg, Christopher A G; Rajan, Sreekanth; Shkumatov, Alexander V et al. (2013) The molecular basis of iron-induced oligomerization of frataxin and the role of the ferroxidation reaction in oligomerization. J Biol Chem 288:8156-67
Oglesbee, Devin; Kroll, Charles; Gakh, Oleksandr et al. (2013) High-throughput immunoassay for the biochemical diagnosis of Friedreich ataxia in dried blood spots and whole blood. Clin Chem 59:1461-9
Li, Hongqiao; Gakh, Oleksandr; Smith 4th, Douglas Y et al. (2013) Missense mutations linked to friedreich ataxia have different but synergistic effects on mitochondrial frataxin isoforms. J Biol Chem 288:4116-27
Vaubel, Rachael A; Isaya, Grazia (2013) Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia. Mol Cell Neurosci 55:50-61

Showing the most recent 10 out of 45 publications